(Q113893304)

English

Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Retrospective Chart Review of Children With Primary Immunodeficiencies (PID) Who Received Targeted Therapy of Interstitial Lymphocytic Lung Disease (ILLD) With Abatacept or Rituximab. (English)

0 references

start time

7 September 2020

0 references

end time

September 2021

0 references

number of participants

30

0 references

research intervention

rituximab

0 references

immunologic factor

0 references

disease-modifying antirheumatic drug

0 references

checkpoint inhibitor

0 references

abatacept

0 references

immunological antineoplastic agent

0 references

alkylating antineoplastic agent

0 references

mechanism of action

0 references

immunosuppressive drug

0 references

research subject recruitment status

unknown

0 references

maximum age

18 year

0 references

study type

observational study

0 references

Identifiers

ClinicalTrials.gov ID

NCT04572620

0 references

(Q113893304)

Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)